(Total Views: 387)
Posted On: 02/22/2021 1:24:53 PM
Post# of 155803
Re: Number1Stocker #79267
Nah, they are both CCR5 antagonists.
If another drug shows a meaningful impact using a different MOA, they may consider trying them together to see how the results compare. But, that is going to depend on a number of factors.
For example, if the secondary drug is downstream, its effect will be reduced due to Leronlimab working upstream.
If another drug shows a meaningful impact using a different MOA, they may consider trying them together to see how the results compare. But, that is going to depend on a number of factors.
For example, if the secondary drug is downstream, its effect will be reduced due to Leronlimab working upstream.
(1)
(0)
